Rafael Holdings, Inc. (RFL): Insider Trading, Congress Trades & Research | Tormere

RFL

$1.07-0.93%visit website

Rafael Holdings, Inc.

Market Cap

$56M

Live price × SEC shares (Oct 26, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

0.73

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jul 2026 · negative earnings

P/S (TTM)

63.9

TTM to Jul 2026 · revenue

P/B

0.8

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q1 FY2026 Oct 31, 2025	Q2 FY2026 Jan 31, 2026	Q3 FY2026 Apr 30, 2026	Q4 FY2026 Jul 31, 2026	TTM Jul 31, 2026
Revenue	240	211	179		874
Research & development	7,484	4,529	4,853	7,467	24,333
Operating income	(10,141)	(6,655)	(6,870)	(9,731)	(33,397)
Interest expense	160	161	6	6	333
Pretax income	(9,787)	(6,279)	(2,892)	(8,997)	(27,955)
Income tax	10.0	48.0	6.0	(65.0)	(1.0)
Net income	(9,816)	(6,417)	(4,226)	(9,176)	(29,635)
EPS (basic) ($)	(0.19)	(0.13)	(0.08)		(0.58)
EPS (diluted) ($)	(0.19)	(0.13)	(0.08)		(0.58)
Weighted avg. shares (basic)	51,184	51,226	51,230
Weighted avg. shares (diluted)	51,184	51,226	51,230

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-K filed Oct 29, 2026, period ended Jul 31, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 35 more quarters, back to Jan 2017, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

Yahoo · 2026-11-03

Guggenheim's healthcare conference will include a fireside chat with Rafael Holdings in Boston.

Stock Titan · 2026-11-03

Rafael Holdings, Inc. (NYSE:RFL) Shares Shorted: Short Interest Down 55.9% in October

MarketBeat · 2026-10-31

Rafael Holdings Announces NDA Submission for Remibetadex and Reports Fiscal Year 2026 Financial Results

Fintel · 2026-10-29

Rafael Holdings' Subsidiary Files NDA for Remibetadex in Niemann

GuruFocus · 2026-10-29

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Yahoo · 2026-10-29

Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C

Yahoo · 2026-10-29

Rafael Holdings Q4 EPS $(0.18) Up From $(0.28) YoY, Sales $244.000K Down From $350.000K YoY

Benzinga · 2026-10-29

Rafael Holdings Files New Drug Application To FDA For Approval Of Remibetadex To Treat Neurovisceral Manifestations Of Niemann-Pick Disease Type C

Benzinga · 2026-10-29

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal

SeekingAlpha · 2026-10-15

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

Yahoo Finance · 2026-10-04

Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss

Yahoo Finance · 2026-10-01

We're Keeping An Eye On Rafael Holdings' (NYSE:RFL) Cash Burn Rate

Simply Wall St · 2026-10-01

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

Yahoo Finance · 2026-09-30

Rafael Holdings stock tumbles 25% as drug trial misses goal

Yahoo Finance · 2026-09-30

Informational purposes only, not investment advice.

Corporate Events (8-K)

1 filing in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 29, 2026 accepted 8:16 AM ET	2.02Earnings release7.01Reg FD disclosure8.01Other events	Document SEC ↗